PFO ACCESS Registry
Study Details
Study Description
Brief Summary
Closure of Patent Foramen Ovale with the AMPLATZER® PFO OCCLUDER in patients with at least two cryptogenic strokes due to presumed paradoxical embolism through a patent foramen ovale and who have failed conventional therapy.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
The primary objective of the PFO Access Registry is to allow access to the AMPLATZER PFO Occluder in subjects with a PFO who have already experienced at least two cryptogenic strokes due to presumed paradoxical embolism through a patent foramen ovale and who have failed conventional drug therapy.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria:
Patent foramen ovale (PFO); recurrent cryptogenic stroke; failed antiplatelet/anticoagulant therapy
Exclusion Criteria:
International normalized ration (INR) outside of 2-3; intracardiac thrombus (subjects may be enrolled after resolution of thrombus)
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Abbott Medical Devices
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AGA-011
- G060145
- NCT00557479